NCT02241551终止2 期
Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Nathan Bahary, MD1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control
研究概览
简要总结
This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients must meet the following criteria within 28 days of randomization (unless otherwise indicated) to be enrolled in the protocol:
- •Histologically or cytologically proven adenocarcinoma of the pancreas. If the patient has mixed tumor with predominant adenocarcinoma pathology, they can be enrolled.
- •Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)
- •The tumor must be deemed as being borderline resectable. Final CT confirmation of surgical staging/ eligibility will be at the discretion of the pancreatic surgeon of the patient.
- •Disease is confined to locoregional site as confirmed by the CT and / or diagnostic staging laparoscopy to avoid occult peritoneal deposits. Diagnostic laproscopy will be only if absolutely required
- •Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT
- •Screening Endoscopic ultrasound if done prior to consent but within 6 weeks of expected randomization date it may be used.
- •Karnofsky performance status greater than or equal to 70 or Eastern Cooperative Oncology Group (ECOG) performance of 0-
- •Age > 18
- •Estimated life expectance > 12 weeks
- •If female patient is of child bearing potential, she must have a negative serum pregnancy test (βhCG) documented up to 72hrs prior to administration of first study drug
- •Patient has screening blood work performed which includes the following (should be drawn ≤ 14 days prior to randomization)
- •absolute neutrophil count (ANC) > 1.5 x 109/L
- •Platelet count ≥ 100000/mm3
- •Hemoglobin (HgB) ≥ 9g/dL
- •aspartate aminotransferase (AST),Alanine Aminotransferase (ALT)≤ 2.5 x upper limit of normal (ULN) Total Bilirubin ≤ ULN
- •Serum Cr within normal limits (WNL)
- •Coagulation studies with Prothrombin Time and International Normalized Ratio (PT/INR) and partial thromboplastin time (PTT) within normal limits (±15%). • Patient has a urinalysis obtained (≤14 days prior to randomization) and the results are deemed not clinically significant by the investigator.
- •Patient has no evidence of jaundice at the time of enrolment. If stent is required to alleviate jaundice, it should be metallic. If patient has a previously placed stent and this is plastic, this should be changed to metallic.
- •Patient's pain symptoms have remained stable with no adjustment to analgesics within 7 days prior to randomization. Patient must be able to swallow entreat medications with no requirement for a feeding tube. Patient's must not have intractable nausea or vomiting which prohibits the patient from oral medications
- •Diabetes must be controlled prior to enrollment
- •Disease must be encompassed in a reasonable SBRT "portal" as defined by the treating radiation oncologist
排除标准
- •Ineligible Histology including non-adenocarcinomas, adenosquamous carcinoma, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct and ampullary carcinomas
- •Evidence of distant metastasis on upright chest x-ray, CT or other staging studies
- •Subjects with recurrent disease
- •Prior radiation therapy to the upper abdomen or liver at the discretion of the treating radiation oncologist could impair delivery of the prescribed radiation treatment
- •Prior chemotherapy
- •Subjects in their reproductive age who are breast feeding or have a positive pregnancy test
- •Any co-morbid condition of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician
- •Concurrent active infection
- •Previous or current malignancies of other histologies within the last 3 yrs prior to randomization; with the exception of cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer
- •Patient with known historical or active infection with HIV, Hepatitis B or Hepatitis C
- •Patient who has undergone recent major surgery, other than diagnostic surgical procedure within 4 weeks prior to randomization.
- •Patient who has a history of allergy or hypersensitivity to any of the study drugs.
- •Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
- •Patients with greater than 2 screening peripheral neuropathy.
研究组 & 干预措施
gemcitabine/nab-paclitaxel
Experimental
three cycles of treatment in the gemcitabine/nab-paclitaxel
干预措施: gemcitabine/nab-paclitaxel (Drug)
mFOLFIRINOX
Experimental
6 cycles in the mFOLFIRINOX
干预措施: mFOLFIRINOX (Drug)
结局指标
主要结局
Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control
时间窗: up to 5 years
Efficacy: pathological complete response (pCR) and R0 resection. Safety: Grade 4 toxicity.
次要结局
- R0 Resection Rates in Borderline Resectable Pancreatic Cancer(Up to 5 years)
- Incidence of Grade 3 and 4 Toxicities for the 2 Chemotherapy Regimens That Occur After Cycle 1 Day 1(Up to 5 years)
- Ca19-9 Response to Neoadjuvant Chemotherapy(Up to 5 years)
- Time to Disease Progression(Up to 5 years)
- Measurement of Biomarkers (SPARC, RM1 and SMAD4) in Tissues(Up to 5 years)
- Radiological Response Rate to Therapy(Up to 5 years)
- Quality of Life Effects of Chemotherapy on Patients Receiving Chemotherapy and SBRT(Up to 5 years)
研究者
Nathan Bahary, MD
Associate Professor
University of Pittsburgh
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Trial of Chemoradiation and Pembrolizumab in Patients With Rectal CancerRectal CancerRectal NeoplasmNCT02586610Osama Rahma, MD
已完成
2 期
A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric AdenocarcinomaStomach NeoplasmsNeoadjuvant TherapyChemoradiotherapyChemotherapyNCT02301481Chinese Academy of Medical Sciences71
Unknown
2 期
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT01054482The First Affiliated Hospital of Guangzhou Medical University120
已完成
2 期
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract CancerHigh Grade Upper Tract Urothelial CarcinomaNCT02412670ECOG-ACRIN Cancer Research Group36
进行中（未招募）
2 期
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)Resectable SarcomaNCT04968106Institut Bergonié66